UK biopharmaceutical company Kymab may attack experiments done by US biotechnology giant Regeneron creating genetically modified mice with splices of human genomes, as it defends its proposed patent for a human rat.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?
Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.

For information on rights and reprints, contact subscriptions@lawyerly.com.au